ADENOVIRAL MEDIATED ISLET GENE TRANSFER

腺病毒介导的胰岛基因转移

基本信息

  • 批准号:
    2763528
  • 负责人:
  • 金额:
    $ 6.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-09-30 至 2000-09-29
  • 项目状态:
    已结题

项目摘要

Diabetes mellitus is a common disorder, estimated to occur in 5 percent of the population of the United States. Diabetes is a major cause of premature death from vascular disease and the leading cause of blindness in working-age adults, of nontraumatic lower extremity amputations, and of renal failure requiring dialysis and transplantation. About 10-15 percent of the total health care budget in the US is spent on diabetes. Thus, diabetes represents a serious burden to the individual and to society. Studies on the pathogenesis of diabetes (both type I and II) indicate that impaired Beta-cell function accounts for the majority of the defects. Although the pathogenesis of the two diseases is different, the underlying metabolic cause of both forms of diabetes is a failure of the pancreatic Beta cells to provide insulin in an amount sufficient to meet the body's needs, leading to hyperglycemia. Improperly controlled hyperglycemia is directly responsible for the development of the specific and non-specific complications of the diabetic state. Beta-cell dysfunction is present in all diabetic patients. Islet allografts may also exhibit Beta-cell dysfunction. In glucose-regulated Beta-cell function, glucose uptake and metabolism are obligatory steps in sending the message which results in an increase in intracellular Ca2+, leading to insulin biosynthesis and secretion. These processes are directly regulated to two proteins: glucose transporters and glucokinase. It was proposed that GLUT2 and glucokinase may function in tandem as primary elements of the glucose sensing apparatus. By overexpression of these genes in pancreatic islets and Beta-cell lines, a significant increase of insulin release has been demonstrated in glucose-induced response. However, this phenomenon has not been studied using human pancreatic islets. In this proposal, we will transfer these candidate gene(s) into human pancreatic islet tissue by vascular delivery of adenoviral vectors and examine whether specific gene transfer will improve islet Beta-cell function in vitro and in vivo. Specifically, we will further define appropriate conditions to achieve highly efficient (greater than 90 percent) gene transfer to human pancreatic islet tissue by delivering viruses through vascular (arterial infusion) perfusion of the whole pancreas prior to islet isolation. We will then assess the metabolic effects of viral infection and gene transfer (1st, 2nd, 3rd generation adenoviral vectors encoding LacZ reporter gene or other specific therapeutic gene(s) on the functional integrity of islet tissue. Finally we will examine the effectiveness of adenoviral mediated gene transfer to pancreatic islets on the correction of Beta-cell dysfunction for the treatment of Type I and II diabetes by transferring the genes for GLUT2 and glucokinase to human islet tissue.
糖尿病是一种常见的疾病,估计有5%的人患有糖尿病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Kenneth Lewis Brayman其他文献

Kenneth Lewis Brayman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Kenneth Lewis Brayman', 18)}}的其他基金

CLINICAL TRIAL: ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
临床试验:I 型糖尿病患者的胰岛细胞移植
  • 批准号:
    8167147
  • 财政年份:
    2010
  • 资助金额:
    $ 6.79万
  • 项目类别:
CLINICAL TRIAL: UVA ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
临床试验:I 型糖尿病患者的 UVA 胰岛细胞移植
  • 批准号:
    8167168
  • 财政年份:
    2010
  • 资助金额:
    $ 6.79万
  • 项目类别:
CLINICAL TRIAL: UVA ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
临床试验:I 型糖尿病患者的 UVA 胰岛细胞移植
  • 批准号:
    7951490
  • 财政年份:
    2009
  • 资助金额:
    $ 6.79万
  • 项目类别:
CLINICAL TRIAL: ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
临床试验:I 型糖尿病患者的胰岛细胞移植
  • 批准号:
    7951457
  • 财政年份:
    2009
  • 资助金额:
    $ 6.79万
  • 项目类别:
CLINICAL TRIAL: ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
临床试验:I 型糖尿病患者的胰岛细胞移植
  • 批准号:
    7718537
  • 财政年份:
    2008
  • 资助金额:
    $ 6.79万
  • 项目类别:
CLINICAL TRIAL: UVA ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
临床试验:I 型糖尿病患者的 UVA 胰岛细胞移植
  • 批准号:
    7718586
  • 财政年份:
    2008
  • 资助金额:
    $ 6.79万
  • 项目类别:
ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
I 型糖尿病患者的胰岛细胞移植
  • 批准号:
    7606679
  • 财政年份:
    2007
  • 资助金额:
    $ 6.79万
  • 项目类别:
ISLET CELL TRANSPLANTATION IN PATIENTS WITH TYPE I DIABETES
I 型糖尿病患者的胰岛细胞移植
  • 批准号:
    7205497
  • 财政年份:
    2005
  • 资助金额:
    $ 6.79万
  • 项目类别:
ADENOVIRAL MEDIATED ISLET GENE TRANSFER
腺病毒介导的胰岛基因转移
  • 批准号:
    2906389
  • 财政年份:
    1998
  • 资助金额:
    $ 6.79万
  • 项目类别:

相似海外基金

Analysis of transmembrane proteins activity in urological cancers using humanized SCID mouse
使用人源化 SCID 小鼠分析泌尿系统癌症中的跨膜蛋白活性
  • 批准号:
    19K09674
  • 财政年份:
    2019
  • 资助金额:
    $ 6.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
SCID Mouse: Human Xenograft Core
SCID 小鼠:人类异种移植核心
  • 批准号:
    7608570
  • 财政年份:
    2008
  • 资助金额:
    $ 6.79万
  • 项目类别:
SCID Mouse : Human Xenograft Core
SCID 小鼠:人类异种移植核心
  • 批准号:
    7392297
  • 财政年份:
    2007
  • 资助金额:
    $ 6.79万
  • 项目类别:
Core B - SCID Mouse : Human Xenograft Core (Jordan Pober, MD/PhDP.I.)
核心 B - SCID 小鼠:人类异种移植核心(Jordan Pober,医学博士/博士)
  • 批准号:
    6756347
  • 财政年份:
    2004
  • 资助金额:
    $ 6.79万
  • 项目类别:
CORE--NOD/SCID MOUSE
核心--NOD/SCID鼠标
  • 批准号:
    6967796
  • 财政年份:
    2004
  • 资助金额:
    $ 6.79万
  • 项目类别:
EXPERIMENTAL ANALYSIS OF VASCULER CHANGES IN CHRONIC ALLOGRAFT REJECTION USING HUMANIZED SCID MOUSE MODEL.
使用人源化 SCID 小鼠模型对慢性同种异体移植排斥中的血管变化进行实验分析。
  • 批准号:
    14571526
  • 财政年份:
    2002
  • 资助金额:
    $ 6.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The heat shock protein(HSP) was investigated as the pathogenesis of focal infection with tonsil by the SCID mouse model
通过SCID小鼠模型研究热休克蛋白(HSP)作为扁桃体局灶性感染的发病机制
  • 批准号:
    14571629
  • 财政年份:
    2002
  • 资助金额:
    $ 6.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of patient-like SCID mouse model by orthotopically implanting primary cultured cells from surgically-resected lung cancer tissues.
通过原位植入手术切除的肺癌组织的原代培养细胞建立类患者 SCID 小鼠模型。
  • 批准号:
    14571269
  • 财政年份:
    2002
  • 资助金额:
    $ 6.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CORE--NUDE/SCID MOUSE FACILITY
核心——NUDE/SCID 小鼠设施
  • 批准号:
    6563716
  • 财政年份:
    2001
  • 资助金额:
    $ 6.79万
  • 项目类别:
CORE--NOD/SCID MOUSE
核心--NOD/SCID鼠标
  • 批准号:
    6496710
  • 财政年份:
    2001
  • 资助金额:
    $ 6.79万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了